CD8A and hepatocellular carcinoma: This review article provides the interplay between TAMs and CD8+ T cells specifically contribute to the pathogenesis, progression, and clinical outcomes of HBV-related HCC, and what therapeutic strategies, both current and emerging, target these immune components, considering their limitations and potential for improving patient outcomes.